NOVN.CH

113.38

-2.12%↓

SOON.CH

204.8

-0.19%↓

NOVN.CH

113.38

-2.12%↓

SOON.CH

204.8

-0.19%↓

NOVN.CH

113.38

-2.12%↓

SOON.CH

204.8

-0.19%↓

NOVN.CH

113.38

-2.12%↓

SOON.CH

204.8

-0.19%↓

NOVN.CH

113.38

-2.12%↓

SOON.CH

204.8

-0.19%↓

Home・Aktien・Lonza Group AG
Search

Lonza Group AG

Open

BrancheGesundheitswesen

504.2 1.84

Starkes Kaufsignal

Kursupdate 2. Juni 2026, 08:41 UTC

BuySell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

493.7

Max

505.8

Schlüsselkennzahlen

By Trading Economics

Einkommen

57M

483M

Verkäufe

-621M

3B

KGV

Branchendurchschnitt

37.879

50.102

Dividendenrendite

1.01

Gewinnspanne

16.345

Angestellte

20,000

EBITDA

-181M

822M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+35.16% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

1.01%

2.33%

Nächstes Ergebnis

22. Juli 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-4.3B

34B

Vorheriger Eröffnungskurs

502.36

Vorheriger Schlusskurs

504.2

Nachrichtenstimmung

By Acuity

35%

65%

92 / 344 Ranking in Healthcare

Lonza Group AG Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. März 2026, 17:44 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

DJ

Lesen

28. Jan. 2026, 06:15 UTC

Ergebnisse

Lonza Sales Grow on New Contract Momentum

DJ

Lesen

23. Juli 2025, 08:30 UTC

Ergebnisse
Wichtige Markttreiber

Lonza Shares Rise After Outlook Lift for Core Business

DJ

Lesen

15. Mai 2026, 10:45 UTC

Market Talk

Contract Drug Manufacturers to Benefit From U.S. Pharma Onshoring Push -- Market Talk

DJ

Lesen

8. Mai 2026, 13:44 UTC

Market Talk
Ergebnisse

Lonza Update Should Reassure on Outlook -- Market Talk

DJ

Lesen

9. März 2026, 10:34 UTC

Market Talk

Lonza Might Disappoint Investors With Capsule Business Valuation -- Market Talk

DJ

Lesen

6. März 2026, 17:12 UTC

Akquisitionen, Fusionen, Übernahmen

Correct: Lonza to Sell Capsules & Health Ingredients Business to Lone Star Funds

DJ

Lesen

6. März 2026, 17:10 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza: Total Undiscounted Proceeds Expected to Be at or Above CHF3B

DJ

Lesen

6. März 2026, 17:09 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza to Retain 40% Stake in CHI

DJ

Lesen

6. März 2026, 17:08 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza Will Receive Upfront Proceeds of CHF1.7B

DJ

Lesen

6. März 2026, 17:07 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza: Transaction Expected to Close in 2H

DJ

Lesen

6. März 2026, 17:07 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza: This Is for Enterprise Value of CHF2.3B at Closing

DJ

Lesen

6. März 2026, 17:06 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza to Sell Capsules & Health Ingredients Business Lone Star Funds

DJ

Lesen

28. Jan. 2026, 12:04 UTC

Market Talk
Ergebnisse

Lonza Results Show a Company in Good Shape -- Market Talk

DJ

Lesen

28. Jan. 2026, 05:35 UTC

Ergebnisse

Lonza Anticipates 2026 Core EBITDA Margin to Reach Level Above 32%

DJ

Lesen

28. Jan. 2026, 05:34 UTC

Ergebnisse

Lonza Anticipates 2026 Sales Growth of 11-12% at CER

DJ

Lesen

28. Jan. 2026, 05:33 UTC

Ergebnisse

Lonza Issues 2026 View

DJ

Lesen

28. Jan. 2026, 05:32 UTC

Ergebnisse

Lonza 2025 Core Ebitda Margin 31.6%

DJ

Lesen

28. Jan. 2026, 05:32 UTC

Ergebnisse

Analysts Saw Lonza 2025 Core Ebitda at CHF2.27B

DJ

Lesen

28. Jan. 2026, 05:32 UTC

Ergebnisse

Lonza 2025 Core Ebitda CHF2.06B

DJ

Lesen

28. Jan. 2026, 05:30 UTC

Ergebnisse

Analysts Saw Lonza 2025 Sales at CHF7.54B

DJ

Lesen

28. Jan. 2026, 05:30 UTC

Ergebnisse

Lonza 2025 Sales CHF6.53B

DJ

Lesen

27. Okt. 2025, 08:24 UTC

Market Talk

Lonza on Track to Meet Long-Term Goals -- Market Talk

DJ

Lesen

23. Okt. 2025, 10:53 UTC

Market Talk
Ergebnisse

Lonza Set to Recover as Contracts Flow in -- Market Talk

DJ

Lesen

23. Juli 2025, 08:00 UTC

Market Talk
Ergebnisse

Lonza Nudges Up Full-Year Guidance for Core Business After Good Results -- Market Talk

DJ

Lesen

23. Juli 2025, 04:44 UTC

Ergebnisse

Lonza 1H Sales Grew 19% at Constant Currency

DJ

Lesen

23. Juli 2025, 04:43 UTC

Ergebnisse

Lonza 1H Core Ebitda Margin 29.6%

DJ

Lesen

23. Juli 2025, 04:43 UTC

Ergebnisse

Lonza: Margins Will Be Only Minimally Affected

DJ

Lesen

23. Juli 2025, 04:42 UTC

Ergebnisse

Lonza Expects FX Headwind of -2.5% to -3.5% on 2025 Sales and Core Ebitda

DJ

Lesen

23. Juli 2025, 04:42 UTC

Ergebnisse

Lonza: This Is Mainly From Weakening of U.S. Dollar

DJ

Lesen

Peer-Vergleich

Kursveränderung

Lonza Group AG Prognose

Kursziel

By TipRanks

35.16% Vorteil

12-Monats-Prognose

Durchschnitt 676.33 CHF  35.16%

Hoch 762 CHF

Tief 630 CHF

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Lonza Group AG – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

6

Buy

0

Halten

0

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Lonza Group AG – Dist abgegeben haben.

Stimmung

By Acuity

92 / 344 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Andere Aktien aus dem Sektor

NOVN.CH

Novartis AG

113.38

↓-2.12%

SOON.CH

Sonova Holding AG

204.8

↓-0.19%
help-icon Live chat